drugset / Trial / NCT05499065
Real-time Margin Assessment in Head and Neck Cancer
NaSingle-groupOpen-labelTreatment
Summary
To investigate if the combination of fresh frozen sectioning based on cetuximab-800CW can enhance tumor-positive margin detection intra-operatively.
Timeline
- Start
- 2023-03-01
- Primary completion
- 2024-10-23
- Completion
- 2025-01-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab-IRDye800 | Monoclonal antibody | 15 mg | — |
| Background | Cetuximab | Monoclonal antibody | 75 mg | — |